Cyrus Harmon - Olema Pharmaceuticals Chief Director
| OLMA Stock | USD 4.60 0.06 1.29% |
Insider
Cyrus Harmon is Chief Director of Olema Pharmaceuticals
| Age | 53 |
| Address | 780 Brannan Street, San Francisco, CA, United States, 94103 |
| Phone | 415 651 3316 |
| Web | https://olema.com |
Latest Insider Transactions
| 2024-07-29 | Disposed of 4066 shares @ 15.58 | View | |
| 2024-07-11 | Disposed of 5000 shares @ 12.26 | View | |
| 2024-06-28 | Disposed of 20000 shares @ 10.77 | View | |
| 2024-06-03 | Disposed of 5000 shares @ 10.93 | View | |
| 2024-05-31 | Disposed of 15000 shares @ 9.41 | View | |
| 2024-05-06 | Disposed of 5000 shares @ 10.92 | View | |
| 2024-04-30 | Disposed of 15000 shares @ 9.51 | View | |
| 2024-03-28 | Disposed of 20000 shares @ 10.97 | View | |
| 2024-02-29 | Disposed of 25000 shares @ 12.41 | View |
Cyrus Harmon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Cyrus Harmon against Olema Pharmaceuticals stock is an integral part of due diligence when investing in Olema Pharmaceuticals. Cyrus Harmon insider activity provides valuable insight into whether Olema Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Olema Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Olema Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Cyrus Harmon over six months ago Disposition of 934 shares by Cyrus Harmon of Olema Pharmaceuticals at 15.55 subject to Rule 16b-3 | ||
Cyrus Harmon over six months ago Disposition of 4066 shares by Cyrus Harmon of Olema Pharmaceuticals at 15.58 subject to Rule 16b-3 | ||
Cyrus Harmon over six months ago Disposition of 5000 shares by Cyrus Harmon of Olema Pharmaceuticals at 12.26 subject to Rule 16b-3 | ||
Cyrus Harmon over six months ago Disposition of 5000 shares by Cyrus Harmon of Olema Pharmaceuticals at 10.93 subject to Rule 16b-3 |
Olema Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3315) % which means that it has lost $0.3315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5176) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2025, Return On Tangible Assets is expected to decline to -0.33. The current year's Return On Capital Employed is expected to grow to -0.45. At present, Olema Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 8.7 M, whereas Total Assets are forecasted to decline to about 208 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Adam Levy | Zentalis Pharmaceuticals Llc | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Jonathan MD | Erasca Inc | 53 | |
| Meena Rao | Zentalis Pharmaceuticals Llc | N/A | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Filip MD | Monte Rosa Therapeutics | 51 | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Annick Deschoolmeester | Pharvaris BV | 52 | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| Sonia DPHIL | PepGen | 38 | |
| RA MSc | Pharvaris BV | 44 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Joan JD | Pharvaris BV | 60 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Michael Alley | AN2 Therapeutics | N/A | |
| Michael Gait | PepGen | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| James McArthur | PepGen | 63 | |
| Niels Svenstrup | PepGen | 55 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 |
Olema Pharmaceuticals Leadership Team
Elected by the shareholders, the Olema Pharmaceuticals' board of directors comprises two types of representatives: Olema Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olema. The board's role is to monitor Olema Pharmaceuticals' management team and ensure that shareholders' interests are well served. Olema Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olema Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD Moriarty, Corporate Secretary | ||
| Peter Kushner, CoFounder Fellow | ||
| PharmD Faltaos, VP Pharmacology | ||
| Kinney Horn, Chief Officer | ||
| Cyrus Harmon, Chief Director | ||
| Courtney Dugan, VP Communications | ||
| John Moriarty, Chief VP | ||
| Moriarty ESQ, Corporate Secretary | ||
| Shane MBA, Chief Officer | ||
| Julie Dexter, Senior People | ||
| Courtney OKonek, Vice Communications | ||
| Naseem MD, Chief Officer | ||
| David Myles, Chief Officer | ||
| Geoffrey Mogilner, Vice Communications | ||
| Shawnte JD, Chief Secretary | ||
| Sasha CPA, VP Controller |
Olema Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Olema Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 128.46 M | ||||
| Shares Outstanding | 74.24 M | ||||
| Shares Owned By Insiders | 3.21 % | ||||
| Shares Owned By Institutions | 96.79 % | ||||
| Number Of Shares Shorted | 8.41 M | ||||
| Price To Book | 1.74 X | ||||
| EBITDA | (104.58 M) | ||||
| Net Income | (96.66 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.